anti her2  (InvivoGen)

Journal: Molecular Therapy Oncology

Article Title: Combined radiation and Listeria immunotherapy induces cytotoxic immunity that correlates with improved outcome in dogs with osteosarcoma

doi: 10.1016/j.omton.2026.201243

Figure Lengend Snippet: Pilot study outline and timeline Dogs were screened 4 to 10 days prior to receiving immunotherapy to confirm general health status and histopathological diagnosis of OSA. Dogs received 2 doses of 8Gy palliative radiation (RT1 and RT2) on consecutive days followed by the first of 8 scheduled Lm-LLO-HER2 treatments (V#1–8). CBC, complete blood count; CS, chemistry screen; UA, urinalysis; cTnI, cardiac troponin I.

Article Snippet: This study was supported in part by Advaxis who supplied the Lm-LLO-HER2 and the Mason Cancer Research Fund.

Techniques: Biomarker Discovery

Journal: Molecular Therapy Oncology

Article Title: Combined radiation and Listeria immunotherapy induces cytotoxic immunity that correlates with improved outcome in dogs with osteosarcoma

doi: 10.1016/j.omton.2026.201243

Figure Lengend Snippet: Effects of Lm-LLO-HER2 on body temperature (A) Temperatures for all dogs receiving Lm-LLO-HER2 were measured at each time point at each vaccination. (B) The change in temperature between 0 and 4 h was plotted for all dogs for each vaccination. Circles represent values lower than the 5 th percentile and higher than the 95 th percentile.

Article Snippet: This study was supported in part by Advaxis who supplied the Lm-LLO-HER2 and the Mason Cancer Research Fund.

Techniques:

Journal: Molecular Therapy Oncology

Article Title: Combined radiation and Listeria immunotherapy induces cytotoxic immunity that correlates with improved outcome in dogs with osteosarcoma

doi: 10.1016/j.omton.2026.201243

Figure Lengend Snippet: Series of thoracic radiographs of dog 005 showing evidence of suspected pulmonary metastatic disease (A) One nodule was first identified at the time of the 8 th Lm-LLO-HER2 treatment, day 156 (arrow). (B) Nodule enlarged within 2 months (arrow) with a new second indistinct nodule in the caudal lung (arrowhead). (C and D) Both nodules have progressed. (E) Original nodule has improved (arrow) and second nodule is not clearly identified. (F) Both nodules have progressed with a third nodule in the caudoventral lung (long arrow). (G and H) Continued nodule progression with at least one additional nodule at 555 days (long thin arrow). (I) Progressive disease with multiple ill-defined masses in the caudal lung (long thin arrows). The dog did not receive a booster vaccine at the first 2-months post treatment time point due to a lack of IACUC approval for repeat vaccines at that time. The dog received Lm-LLO-HER2 again on day 274, 345, and 408. Only right lateral radiographs are shown but left lateral and VD views confirm these findings.

Article Snippet: This study was supported in part by Advaxis who supplied the Lm-LLO-HER2 and the Mason Cancer Research Fund.

Techniques: Vaccines

Journal: Molecular Therapy Oncology

Article Title: Combined radiation and Listeria immunotherapy induces cytotoxic immunity that correlates with improved outcome in dogs with osteosarcoma

doi: 10.1016/j.omton.2026.201243

Figure Lengend Snippet: Survival outcomes for dogs with appendicular osteosarcoma (A) Swimmer’s plot for vaccinated dogs with primary appendicular OSA. TTpP, time to pseudoprogression of primary tumor (as determined by radiography); TTP, time to radiographic progression; OST, overall survival time; ∗, time to pseudoprogression of lung lesion; ˆ, time of amputation which coincided with disease progression; red star, euthanized at time of progression. (B) Kaplan-Meier survival curve showing dogs treated with palliative RT (pRT) plus Lm-LLO-HER2 and a historical control group treated with pRT alone. The Mantel-Cox log rank test was used to detect differences in the two survival curves. Tick marks indicate censored patients.

Article Snippet: This study was supported in part by Advaxis who supplied the Lm-LLO-HER2 and the Mason Cancer Research Fund.

Techniques: Biomarker Discovery, Control

Journal: Molecular Therapy Oncology

Article Title: Combined radiation and Listeria immunotherapy induces cytotoxic immunity that correlates with improved outcome in dogs with osteosarcoma

doi: 10.1016/j.omton.2026.201243

Figure Lengend Snippet: Effects of Lm-LLO-HER2 on gene expression in PBMCs nCounter analysis of PBMCs at the time of the fourth Lm-LLO-HER2 administration compared to baseline in LT and ST survivors. (A) Heatmap showing genes that are differentially expressed genes (fold change ≥1.5 and ≤−1.5; p ≤ 0.05) following Lm-LLO-HER2 administration in LT (left) and ST (right) survivors. Blue bar represents pre-treatment values; orange bars represent post-treatment values. Mean-subtracted log 2 normalized counts are shown for DEG between baseline and fourth vaccination time point. (B) Volcano plots showing individual genes that are differentially expressed following Lm-LLO-HER2 administration for LT and ST survivors. The log ratio of the fold change is displayed on the x axis and the negative log of the adjusted p value is on the y axis. (C) Cell-type profiling within PBMCs for LT (red bar) and ST (blue bar) survivors at baseline and at the fourth vaccination time point.

Article Snippet: This study was supported in part by Advaxis who supplied the Lm-LLO-HER2 and the Mason Cancer Research Fund.

Techniques: Gene Expression